A hematopoietic transit model was developed to describe the joint effects of reducing influx from pro-B cells and accelerating CD20+ B cell depletion in the blood by inebilizumab.
[British Journal of Clinical Pharmacology]
Sorry, but the selected Zotpress account can't be found.
